Skip to main content
. 2006 Jun 5;103(24):9190–9195. doi: 10.1073/pnas.0603503103

Fig. 5.

Fig. 5.

Immunotherapy restored protective antitumor innate responses and enhanced cross-presentation in MEL15. (A) PBMCs were obtained from MEL15 during vaccination or after CTLA-4 blockade, and NKG2D expression on gated CD8+ T cells was determined with flow cytometry. (B) PBMCs were obtained from MEL15 during vaccination or after CTLA-4 blockade and used to generate dendritic cells. These cells were loaded with K008-T melanoma cells coated in early or late MEL15 sera and then matured with LPS. Purified CD8+ T cells from the same time points were then stimulated in vitro with the respective tumor-loaded dendritic cells for 7 days. IFN-γ production was measured by ELISPOT against the indicated targets. (C) MEL15 CD8+ T cells were purified from PBMCs collected during vaccination or after CTLA-4 blockade and tested for IFN-γ production against the indicated targets without prior in vitro stimulation. Melanoma inhibitor of apoptosis protein (ML-IAP) is a previously characterized tumor rejection antigen (13).